Selective CDK4/6 Inhibitors: A New Paradigm With Expanding Application in Cancer Care

Join us for a dynamic, interactive satellite symposium at ASCO 2017 on the latest evidence-based strategies for using selective CDK4/6 inhibitors in multiple types of malignancies! Our CME-certified event will promote engagement with the expert presenters and your peers.

Not an official event of the 2017 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.


  • Welcome and Introduction
  • Targeting CDK4/6 in Patients With Cancer
  • Clinical Development of Selective CDK4/6 Inhibitors
  • Extending the Use of CDK4/6 Inhibitors Beyond ER-Positive Breast Cancer
  • Closing Remarks and Audience Question and Answer Session


Date / Time
Event Details


Richard Finn, MD

Associate Professor of Medicine
Division of Hematology-Oncology
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Gary K. Schwartz, MD

Professor of Medicine
Department of Medicine
Columbia University
Chief, Division of Hematology and Oncology
Department of Medicine
Columbia University Medical Center
New York, New York

Geoffrey Shapiro, MD, PhD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Early Drug Development Center
Dana-Farber Cancer Institute
Boston, Massachusetts


Program Overview
You are invited to a CME-certified satellite symposium at ASCO 2017 on the increasing role of selective CDK4/6 inhibitors in the management of patients with different types of cancer.

The goal of this activity is to improve participants’ understanding of selective CDK4/6 inhibitors and their preparedness to effectively and safely use these agents when they become available to treat multiple tumor types beyond breast cancer.

Target Audience
The target audience includes medical oncologists, pathologists, nurses, and other healthcare professionals who care for patients with cancer.

Learning Objectives

  • Discuss the preclinical data and scientific rationale for targeting CDK4/6 in cancer care
  • Know how selective CDK inhibition has improved efficacy and reduced toxicity when compared with first-generation, nonselective CDK inhibitors
  • Evaluate the available clinical data on abemaciclib, palbociclib, and ribociclib in multiple tumor types beyond ER-positive breast cancer
  • Explore current therapeutic strategies and ongoing clinical trials of CDK4/6 inhibitors alone or in combination with other agents
  • Describe the similarities and differences among the CDK4/6 inhibitors
  • Summarize mechanisms of acquired resistance to CDK4/6 inhibitors
  • Identify potential biomarkers of sensitivity to CDK4/6 inhibitors


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
The Annenberg Center requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.